OncLive TV

Dr. Roeker on the Rationale for BTK/Venetoclax Combos in CLL

August 10th 2021

Lindsey Roeker, MD, discusses the rationale for combining venetoclax with BTK inhibitors for use in patients with chronic lymphocytic leukemia.

Dr. Danila on Considerations for Treatment Selection in Nonmetastatic CRPC

August 10th 2021

Daniel C. Danila, MD, discusses factors to consider when selecting a treatment option for patients with nonmetastatic castration-resistant prostate cancer.

Dr. Harris on the Adoption of Immunotherapy in Advanced HCC

August 10th 2021

William P. Harris, MD, discusses the adoption of immunotherapy in advanced hepatocellular carcinoma.

Dr. Lee on the Evolving Treatment Paradigm in Relapsed/Refractory Multiple Myeloma

August 10th 2021

Hans Lee, MD, discusses the evolving treatment paradigm in relapsed/refractory multiple myeloma.

Dr. Jones on the Importance of Immune Checkpoint Inhibitors in CRC

August 10th 2021

Jeremy C. Jones, MD, discusses key lessons learned from the phase 3 KEYNOTE-177 trial.

Dr. Willmott on the Importance of Genetic Testing in Ovarian Cancer

August 9th 2021

Lyndsay Willmott, MD, discusses the importance of genetic testing in ovarian cancer.

Dr. Labaki on Disparities in Mammography Screenings During the COVID-19 Pandemic

August 9th 2021

Chris Labaki, MD, discusses racial disparities with regard to mammography screenings during the COVID-19 pandemic.

Dr. Trinh on the Recovery of Cancer Screening Tests Following First COVID-19 Pandemic Peak

August 9th 2021

Quoc-Dien Trinh, MD, discusses findings from a study examining the temporal changes in cancer tests and diagnoses in a large healthcare system in the United States during the COVID-19 pandemic. 

Dr. Danila on the Integration of Advanced Imaging in Prostate Cancer

August 9th 2021

Daniel C. Danila, MD, discusses the integration of advanced imaging in prostate cancer.

Dr. Lentzsch on the Utility of Cellular Therapies in Multiple Myeloma

August 9th 2021

Suzanne Lentzsch, MD, discusses the utility of cellular therapies in multiple myeloma.

Dr. Mikhael on Treatment Selection for Early Relapse in Multiple Myeloma

August 9th 2021

Joseph Mikhael, MD, discusses treatment selection for early relapse in multiple myeloma.

Dr. Wang on the Rationale for Viral Hepatitis Screening to Prevent HCC

August 9th 2021

Su H. Wang, MD, MPH, discusses the rationale for the integration of viral hepatitis screening and care in a hospital system as the first steps for preventing liver cancers like hepatocellular carcinoma.

Garvin on the Benefits of CAR T-Cell Therapy in Non-Hodgkin Lymphoma

August 9th 2021

Kelly Garvin, MA, BSN, RN, discusses the impact of CAR T-cell therapy on the treatment of patients with non-Hodgkin lymphoma.

Washington on Efforts to Address Disparities in Cancer Care

August 9th 2021

Chasity Washington, MPH, CHES, discusses strategies for addressing disparities in cancer care.

Dr. Karim on the Rationale for the CheckMate-73L Trial With Ipilimumab/Nivolumab in NSCLC

August 6th 2021

Nagla Abdel Karim, MD, discusses the rationale for the phase 3 CheckMate-73L trial that is being conducted in patients with stage III non–small cell lung cancer that is unable or not planned to be removed by surgery.

Dr. Mauro on Considerations for Early Treatment Initiation in Myelofibrosis

August 5th 2021

Michael J. Mauro, MD, discusses considerations for early treatment initiation in myelofibrosis.

Dr. Thompson on Future Research Directions in CLL

August 5th 2021

Meghan Thompson, MD, discusses future research directions in chronic lymphocytic leukemia.

Dr. Malhotra on the Rationale to Evaluate Racial Disparities in Lung Cancer Survivors

August 5th 2021

Jyoti Malhotra, MD, MPH, discusses the rationale to evaluate racial disparities in lung cancer survivors.

Dr. Kumar on the Clinical Implications of the AIM Study in Mantle Cell Lymphoma

August 4th 2021

Anita Kumar, MD, discusses the improved efficacy of venetoclax when used in combination with ibrutinib compared with venetoclax or ibrutinib alone in mantle cell lymphoma. 

Dr. Cohen on the Standardization of Triplet Chemotherapy in CRC

August 4th 2021

Stacey A. Cohen, MD, discusses the standardization of triplet-based chemotherapy regimens in colorectal cancer.